#drugrepurposing — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #drugrepurposing, aggregated by home.social.
-
DATE: July 17, 2026 at 12:19AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: New Alzheimer's drug repairs DNA damage and reduces brain inflammation
URL: https://www.sciencedaily.com/releases/2026/07/260711010118.htm
A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.
URL: https://www.sciencedaily.com/releases/2026/07/260711010118.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #AlzheimersDrug #DNARepair #Neuroinflammation #KCL286 #AlzheimersResearch #DNA_damage #BrainHealth #NeurodegenerativeDisease #ClinicalTrials #DrugRepurposing
-
DATE: July 17, 2026 at 12:19AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: New Alzheimer's drug repairs DNA damage and reduces brain inflammation
URL: https://www.sciencedaily.com/releases/2026/07/260711010118.htm
A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation, and targeted multiple disease-related pathways instead of focusing on just amyloid or tau. Since it has already cleared an initial human safety trial, researchers believe it could move more quickly into Alzheimer’s clinical testing.
URL: https://www.sciencedaily.com/releases/2026/07/260711010118.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #AlzheimersDrug #DNARepair #Neuroinflammation #KCL286 #AlzheimersResearch #DNA_damage #BrainHealth #NeurodegenerativeDisease #ClinicalTrials #DrugRepurposing
-
Hospitals and universities repurposing drugs at 90% lower cost
https://www.kcl.ac.uk/news/hospitals-and-universities-repurposing-drugs-at-90-lower-cost
#HackerNews #hospitals #universities #drugrepurposing #costreduction #healthcareinnovation #affordablemedicines
-
Hospitals and universities repurposing drugs at 90% lower cost
https://www.kcl.ac.uk/news/hospitals-and-universities-repurposing-drugs-at-90-lower-cost
#HackerNews #hospitals #universities #drugrepurposing #costreduction #healthcareinnovation #affordablemedicines
-
DATE: June 16, 2026 at 02:48AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: Copper drug clears toxic Alzheimer’s proteins and restores memory
URL: https://www.sciencedaily.com/releases/2026/06/260615033835.htm
A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. The findings point to a potentially fast-tracked new treatment strategy because the drug has already been tested in humans for other neurological conditions.
URL: https://www.sciencedaily.com/releases/2026/06/260615033835.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #CopperDrug #AlzheimersResearch #MemoryRestoration #AmyloidClearing #NeurodegenerativeTherapy #CopperBasedTherapy #BrainHealth #DrugRepurposing #NeurologyNews #CognitiveImprovement
-
DATE: June 16, 2026 at 02:48AM
SOURCE: SCIENCE DAILY MIND-BRAIN FEEDTITLE: Copper drug clears toxic Alzheimer’s proteins and restores memory
URL: https://www.sciencedaily.com/releases/2026/06/260615033835.htm
A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. The findings point to a potentially fast-tracked new treatment strategy because the drug has already been tested in humans for other neurological conditions.
URL: https://www.sciencedaily.com/releases/2026/06/260615033835.htm
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #CopperDrug #AlzheimersResearch #MemoryRestoration #AmyloidClearing #NeurodegenerativeTherapy #CopperBasedTherapy #BrainHealth #DrugRepurposing #NeurologyNews #CognitiveImprovement
-
It's interesting that they paired a talk on ergothioneine, which is primarily thought of as an anti-oxidant (though as discussed in the video, there may be more to its MOA) with hemin, which is a potent pro-oxidant.
There was an in vitro study that suggested hemin might be useful in acute Covid, but it never went anywhere AFAIK. The paper is still interesting for background on hemin as an HO-1 inducer -
https://pmc.ncbi.nlm.nih.gov/articles/PMC8563742/ -
Erythromycin has therapeutic efficacy on muscle fatigue acting specifically on orosomucoid to increase muscle bioenergetics and physiological parameters of endurance [2020]
abstract:
https://pubmed.ncbi.nlm.nih.gov/32777256/preprint can be downloaded here:
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3463265#orosomucoid #fatigue #erythromycin #DrugRepurposing #DrugDevelopment
-
Brayden Yellman, MD | Underappreciated Co-Morbidities in ME/CFS
video uploaded Oct. 16, 2025
https://youtu.be/od0epKW19og[13:03] hydroxyurea used to treat a person with POTS and MCAS
Here's an article on the topic:
Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: retrospective case series [2022]
https://pmc.ncbi.nlm.nih.gov/articles/PMC9388361/"First used 60 years ago for chronic myeloproliferative neoplasms, HU is now standard of care in reducing the severity of sickle cell disease (SCD) (McGann and Ware 2015). In this context, it is of interest that in animal models and human subjects with SCD, medications that reduce MC activation decreased bone pain (Vincent et al. 2013, 2016). HU also inhibits replication of human immunodeficiency virus-1 (HIV-1) and has been used in therapy of cyanotic congenital heart disease (Lori and Lisziewicz 2000; Reiss et al. 2007). A theoretic explanation for effectiveness of HU in these diseases include reducing MC activity independent of anti-proliferative effects. HU could decrease activity and ability of GI mucosal MCs that capture HIV-1 and mediate trans-infection of CD4 + T cells (Jiang et al. 2015). Similarly, HU could reduce the activity of the increased numbers of chymase-containing MCs in lung tissue of congenital heart disease patients and, thereby, decrease severity of these pulmonary and cardiac diseases (Hamada et al. 1999)."
The mechanisms are probably quite complex. One facet is that hydroxyurea increases fetal hemoglobin production and RBC membrane flexibility - which could increase O2 perfusion. Hypoxia activates mast cells.
#MECFS #MCAS #POTS #DrugRepurposing #hydroxyurea #MastCells #immunology
-
📖 💊 New Issue Alert!
Drug Repurposing Vol 2, Issue 1 is out! 5 exciting articles explore AI, chemoinformatics, VR collaboration, and more — showing how existing drugs can find new therapeutic uses.
-
A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID
https://pubs.acs.org/doi/full/10.1021/acsptsci.5c00229lots of details on #pathophysiology in this review
#MECFS #LongCovid #metformin #DrugRepurposing #medicine #health
#WASF3 -
My latest: Medicines Reimagined – #Repurposing Drugs For New Indications via @forbes https://www.forbes.com/sites/judystone/2025/08/27/medicines-reimagined--repurposing-drugs-for-new-indications/ #FDA #DrugRepurposing #MotorNeuronDisease #Malaria #RespiratoryPapilloma #HPV #Remedi4All #iDR25
-
My latest: Medicines Reimagined – #Repurposing Drugs For New Indications via @forbes https://www.forbes.com/sites/judystone/2025/08/27/medicines-reimagined--repurposing-drugs-for-new-indications/ #FDA #DrugRepurposing #MotorNeuronDisease #Malaria #RespiratoryPapilloma #HPV #Remedi4All #iDR25
-
'DrugRxiv' is an open community resource for preprints from the field of #DrugRepurposing. Preprints have increasingly become an essential part of #OpenScience approaches because they combine early and open sharing of #Research results with #OpenAccess and open peer review: https://drugrepocentral.scienceopen.com/collection/DrugRxiv
-
Using machine learning to repurpose old drugs, researchers found a treatment for a rare disease — and it worked. #AI #DrugRepurposing #Healthcare #RareDiseases #MachineLearning
nytimes.com/2025/03/20/hea... -
Using machine learning to repurpose old drugs, researchers found a treatment for a rare disease — and it worked.
https://www.nytimes.com/2025/03/20/health/ai-drug-repurposing-rare-diseases.html
#AI #DrugRepurposing #Healthcare #RareDiseases #MachineLearning -
Using machine learning to repurpose old drugs, researchers found a treatment for a rare disease — and it worked.
https://www.nytimes.com/2025/03/20/health/ai-drug-repurposing-rare-diseases.html
#AI #DrugRepurposing #Healthcare #RareDiseases #MachineLearning -
🌍💊 Gemeinsam für Innovation in der Medizin: Das REPO4EU-Projektkonsortium traf sich am 15. und 16. Jänner 2025 zur General Assembly in Brüssel!
Im Fokus: Die Weiterentwicklung einer Plattform für „drug repurposing“, um bestehende Medikamente für neue therapeutische Ziele nutzbar zu machen.
Wir waren vor Ort und begleiten die Plattformentwicklung in rechtlicher Hinsicht.
Danke an alle Projektpartner*innen.
-
recent review -
Nguyen, J., Nguyen, T. Q., Han, B., & Hoang, B. X. (2024).
Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research, 44(9), 3725–3735. https://doi.org/10.21873/anticanres.17197 -
new paper: "Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?" https://doi.org/10.3389/fmed.2024.1425038
"Rett syndrome (RTT) and Rett-like syndromes [i.e., CDKL5 deficiency disorder (CDD) and FOXG1-syndrome] represent rare yet profoundly impactful neurodevelopmental disorders (NDDs). [..] The current landscape of DR efforts in these syndromes is thoroughly examined [..]"
-
new paper: "Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?" https://doi.org/10.3389/fmed.2024.1425038
"Rett syndrome (RTT) and Rett-like syndromes [i.e., CDKL5 deficiency disorder (CDD) and FOXG1-syndrome] represent rare yet profoundly impactful neurodevelopmental disorders (NDDs). [..] The current landscape of DR efforts in these syndromes is thoroughly examined [..]"
-
"A foundation model for clinician-centered drug repurposing"
There is a strong need for #drugrepurposing given how much clinical trials cost and how many drugs are already developed.
TxGNN predicts indications & contraindications:
https://www.nature.com/articles/s41591-024-03233-x
#medTwitter #medicine #AI -
"A foundation model for clinician-centered drug repurposing"
There is a strong need for #drugrepurposing given how much clinical trials cost and how many drugs are already developed.
TxGNN predicts indications & contraindications:
https://www.nature.com/articles/s41591-024-03233-x
#medTwitter #medicine #AI -
In the inaugural issue of the new #ScienceOpen OA journal, #DrugRepurposing: #Patent Landscaping for #rarediseases 2010–2023
https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647/DRUGREPO.24.1.0012 -
Network-based Multi-omics Disease–Drug Associations Reveal #drugrepurposing Candidates for #COVID19 Disease Phases https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647/DRUGREPO.24.1.0007
-
Machine Learning and Artificial Intelligence in #drugrepurposing — Challenges and Perspectives https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647/DRUGREPO.24.1.0004
-
Big Data-Enabled Repurposing of Clopidogrel for Focal Segmental Glomerulosclerosis Using Network Biology https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647/DRUGREPO.24.1.0006 #drugrepurposing
-
Welcome to the inaugural issue of Drug Repurposing, a #ScienceOpen Open Access, no-APC journal dedicated to all aspects of #drugrepurposing https://drugrepocentral.scienceopen.com/collection/51cc0a58-1974-4d5e-86d5-5b9baaaccea8
-
Just finished the final review with the EU Commission's #HADEA Project Officer and experts for our concluded #H2020 #drugrepurposing project, REPO-TRIAL (https://repo-trial.eu/). We have already made a smooth transition to the much larger #HorizonEurope follow-up project, #REPO4EU (https://repo4.eu/) which is building a a drug repurposing platform. Stay tuned!
-
2024, the year HMPC will publish more and in new ways:
Much of H.M. Pharma Consultancy's work is client confidential, and even our EU projects have restrictions. However, this does not mean that we cannot publish what we generate for ourselves. From the beginning of February we will start to present short discussions on #drugrepurposing #patent applications in certain focus areas of medical research. These will first be highlighted on our preprint server, DrugRxiv at https://drugrepocentral.scienceopen.com/collection/DrugRxiv.
-
International #drugrepurposing #patent applications July-September 2023 https://bit.ly/3uZOZae
-
How to conduct a freedom-to-operate analysis for a #drugrepurposing project, without AI or subscriptions https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647/DRUGARXIV.PR000004.v1 #ScienceOpen
-
Do you know about Drug Repurposing Central, the #publishing and communication platform for the whole #drugrepurposing community? A new player at #ScienceOpen but already flourishing: https://drugrepocentral.scienceopen.com/collection/DrugRepoCentral
-
The roll-up of our RExPO23 #drugrepurposing conference (Stockholm, October 2023) https://youtu.be/tGXMCbwuSVY
-
I will now post regularly about REPO4EU (https://repo4.eu/), the #HorizonEurope project that brings together 28 partners from 10 countries to build a free-to.-use platform for #drugrepurposing. The project is in its second of 5 years, to be followed by infrastructure building.
-
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion. https://doi.org/10.1186/s10020-023-00664-z #PolycysticKidneyDisease #Pkd #Adpkd #DrugRepurposing #SignatureReversion
-
Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion. https://doi.org/10.1186/s10020-023-00664-z #PolycysticKidneyDisease #Pkd #Adpkd #DrugRepurposing #SignatureReversion
-
new research article:
Nuclear lamina erosion-induced resurrection of endogenous retroviruses underlies neuronal aginghttps://doi.org/10.1016/j.celrep.2023.112593
"we verified the loss of B-type lamins inducing resurrection of ERVs as an initiating event of the aging-bound cascade in post-mitotic neurons. Of significance, these aging-related cellular and molecular changes can be alleviated by abacavir"
#Brain #Aging #HERV #EndogenousRetrovirus
#laminB #DrugRepurposing -
This is my latest edited book about #covid19 #drugdevelopment . Herewith, we capture some ongoing trends in this area, including #drugrepurposing and others. You can download the chapters if you register into the system. Please kindly check it out here! 😊 🙂 https://www.intechopen.com/books/11690 @academicchatter @academicsunite